Stephanie Cimo, MD
Hematology & Oncology · New Orleans, LANPI 1194105668
Payments from drug & device makers
Across 43 payments — averaging $24.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Daiichi Sankyo Inc.$430
- Merck$163
- E.r. Squibb & Sons, L.L.C.$67
- Jazz Pharmaceuticals Inc.$52
- Johnson & Johnson$48
- Bayer$46
- plus $253 from 10 others
What the payments were for
- Food & beverage$98393%
- Education$757%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Daiichi Sankyo Inc. | 16 | $430 |
| Merck | 7 | $163 |
| E.r. Squibb & Sons, L.L.C. | 3 | $67 |
| Jazz Pharmaceuticals Inc. | 2 | $52 |
| Johnson & Johnson | 2 | $48 |
| Bayer | 2 | $46 |
| EMD Serono, Inc. | 1 | $40 |
| Tersera Therapeutics LLC | 1 | $32 |
| Incyte Corporation | 2 | $31 |
| Genentech USA, Inc. | 1 | $27 |
| Geron Corporation | 1 | $27 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $24 |
| Novartis | 1 | $22 |
| Pfizer | 1 | $20 |
| Gilead | 1 | $17 |
| Pharmacosmos Therapeutics Inc. | 1 | $14 |
How this compares
$1,058 in reported general payments places this provider in the 15th percentile of 183 hematology & oncology providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TagrissoOsimertinib Mesylate | 12 | $190,740 |
| Anastrozole | 12 | $210 |
| Prochlorperazine Maleate | 20 | $208 |
| Olanzapine | 15 | $68 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in New Orleans
- Marc MatranaNew Orleans$4.6M
- Pedro BarataNew Orleans$4.2M
- Carter DavisNew Orleans$1.6M
- Maissaa JanbainNew Orleans$1.5M
- Lingling duNew Orleans$1.2M
- John ColeNew Orleans$896K
- Cindy LeissingerNew Orleans$432K
- Furhan YunusNew Orleans$422K
- David MorrisonNew Orleans$313K
- Stefan GrantNew Orleans$261K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.